Journal article
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer
Sarah Q To, Edmond M Kwan, Heidi C Fettke, Andrew Mant, Maria M Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenhoefer, Arun A Azad
European Urology | ELSEVIER SCIENCE BV | Published : 2018
Abstract
In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response. To further investigate, we designed a highly sensitive and specific whole ..
View full abstractGrants
Funding Acknowledgements
Arun A. Azad certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Arun Azad: consultant-Astellas, Janssen, Novartis; speakers bureau-Astellas, Janssen, Novartis, Amgen; honoraria-Astellas, Janssen, Novartis, Tolmar, Amgen, Pfizer; scientific advisory board-Astellas, Novartis, Sanofi, Astra-Zeneca, Tolmar, Pfizer; research support-Astellas. Tilman Todenhofer: speakers bureau-Astellas, Janssen; research support-Astellas. Lisa Horvath: research support-Astellas. This work was funded by an NHMRC project grant to Arun Azad, a Cancer Council Victoria Seed Grant to Carmel Pezaro, and Astellas Investigator-Initiated Grants to Arun Azad and Lisa Horvath. Sarah To is supported by an NHMRC fellowship, Edmond Kwan is supported by an NHMRC postgraduate scholarship, Arun Azad is supported by a Victorian Cancer Agency clinical research fellowship.